Trellus Health Interim Results Show Revenue Surge and Fundraising Intent

Trellus Health H1 2025: revenue momentum, pharma traction, and a fundraise on the cards

I’ve just been through Trellus Health’s unaudited interim results for the six months to 30 June 2025. The digital health group is pushing hard into pharma services and clinical trials, showing early commercial traction but also a very tight cash position. Here’s what stands out and why it matters for investors.

The 60-second summary

• Commercial progress: milestone agreement with Johnson & Johnson Health Care Systems Inc in January 2025; preferred vendor status with a leading global CRO in June; Pfizer IBD content licence renewed; AstraZeneca Phase 2 trial licence ongoing.
• Financials: adjusted EBITDA loss of $3.5m, broadly flat year on year; administrative expenses down to $3.3m from $4.1m.
• Revenue: $295k reported for H1. The RNS also quotes year-to-date revenue of $379k and elsewhere “to date” revenue of $428k – the company does not reconcile these different figures in the announcement.
• Cash and runway: $1.6m net cash at 30 June 2025, with runway into early November 2025. Post-period, average monthly burn reduced by c.10% to $440k since 1 August 2025.
• Fundraising: the Board intends to explore a possible raise in the coming weeks. Going concern disclosure highlights a material uncertainty if funding is not secured.

Key numbers from the Trellus Health interim results

Two extra data points are worth noting. The company states “revenue year-to-date is $379k” in the highlights, and later in the notes it says “generated revenues of $428k to date”. That sits above the $295k booked in H1. The RNS does not explain the timing differences, so treat the higher figures as indicative of post-period activity rather than audited revenue.

Commercial progress – J&J pilot data, CRO status and pharma content deals

Trellus is positioning Trellus Elevate – its resilience-based digital support platform – as a tool that improves adherence and engagement for patients with complex chronic conditions. The group is going after three verticals: pharma patient support, clinical trials services, and US health plans.

The J&J agreement is the headline win. Early pilot metrics report 99% patient satisfaction and an average of 50 engagement touchpoints over 28 days. Off the back of that, J&J is broadening enrolment channels. That is exactly the sort of proof-point investors want to see, even if financial details are not disclosed.

A second plank is clinical trials. Trellus has launched Trellus TrialSet, aimed at improving trial recruitment and retention – a persistent industry headache with over 50% of participants failing screening. Preferred vendor status with a global CRO in June is a useful door-opener, and management says they are in late-stage talks with a second global CRO. Again, contract values and timings are not disclosed.

On content and licensing, Pfizer renewed its IBD digital patient support licence in May, and the AstraZeneca Phase 2 IBD trial licence remains in place. The US health plan contract signed in February 2024 is winding down, with final members finishing in September 2025, but management points to positive behavioural outcomes from that small cohort.

Product-wise, Trellus achieved SOC 2 Type II recertification and is starting GDPR certification to enable delivery outside North America. The clinical trial vertical will see its first condition-agnostic programme, broadening beyond IBD. For context, the “About” section reiterates prior data claiming over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits among IBD patients using the methodology – encouraging, though not tied to current revenue.

Cash runway and fundraising – what it means for shareholders

The cash story is blunt. Trellus had $1.6m of net cash at 30 June and expects its runway to reach early November 2025. Since 1 August the company has cut its average monthly burn by around 10% to $440k, which helps but does not change the need for fresh funding.

The Board “intends to explore a possible fundraising over the coming weeks”, with structure and quantum not disclosed. The going concern note is clear that there is a material uncertainty if funding is not secured in time. In practical terms, equity holders should plan for a raise and potential dilution; debt would be harder at this stage, though not ruled out by the company.

Why this update matters for the investment case

• Evidence of traction: J&J pilot expansion, a CRO preferred vendor status, and pharma content renewals point to growing credibility with big partners.
• Operational discipline: administrative costs fell to $3.3m and the company continues to trim cash burn.
• Small but rising revenue: H1 revenue of $295k beats last year’s $50k, and year-to-date numbers cited in the RNS suggest further progress post period.

Balancing that, the entire commercial story still sits on a very small revenue base and short runway. Without contract values or conversion timelines, forecasting is difficult. The fundraising overhang is real and immediate.

Risks and red flags to keep in mind

• Funding risk: management has not yet commenced investor discussions for the potential fundraise according to the notes, and there is no guarantee it completes on the required timeline.
• Going concern: the RNS explicitly flags a material uncertainty if funding is not secured before November 2025.
• Contract visibility: no financial terms or ARR-like metrics are disclosed for pharma, CRO or health plan work.
• Programme wind-down: the US health plan programme is ending in September 2025, reducing one source of activity unless replaced.
• Data inconsistencies: the RNS presents differing “to date” revenue figures ($379k and $428k) alongside $295k reported for H1, with no reconciliation.

My take – cautious optimism, funding first

On the positive side, Trellus is lining up the right customers and producing early engagement metrics that pharma likes to see. Cost control is improving, and the platform is being repurposed sensibly for clinical trials, where better recruitment and retention can save sponsors serious money.

The near-term reality, though, is that the equity story hinges on fundraising terms and the conversion of pilots into paying, scalable contracts. Until those two boxes are ticked, the shares carry elevated execution and dilution risk. If management can land the raise, announce the “at least one” new collaboration they signpost by November, and show that the CRO relationships translate into revenue, the operational upside looks much clearer.

What to watch between now and November

• Details and timing of the proposed fundraising – size, structure, and pricing.
• Any update on J&J beyond the pilot, and whether it becomes a broader commercial roll-out.
• Announcements around the second global CRO and initial TrialSet deployments.
• Cash burn trend – whether the c.$440k per month holds or improves.
• Progress on GDPR certification to open up non-North American clients.

Bottom line: promising commercial signals, but finance comes first. If you are following Trellus Health, the next few weeks should be eventful.